In conclusion, the therapeutic Nrf2 targeting holds great promise for the treatment of lung cancers especially because it has documented a beneficial adjuvant effect in combination with any category of chemotherapeutics, both ROS generating and non-ROS generating agents. This evidence concerns the gene NFE2L2 and lung cancer.